Recent Advance in Treatment of Non Alcoholic Fatty Liver Disease

Abstract

In the developed world, the most common disease in the liver that affects up to a third of people is non- alcoholic fatty liver disease (NAFLD). It is closely linked to metabolic symptoms , particularly obesity and diabetes. This is a growing symptom for cirrhosis, liver-cell carcinoma and hepatic failure. Dietary and genetic factors decide the vulnerability and development of NAFLD. NAFLD can also be involved in cardiovascular disease pathogenesis. Some patients with irregular liver blood tests found by the way. Usually, care is one of exclusion. For the staging of disease, Liver biopsy is important, however new imaging methods and biomarkers arise which can ultimately play their part. NAFLD treatment is not yet firmly based on evidence. The treatment is actually designed to treat elements of metabolic syndrome which may be useful for the liver. The recent clarification of the progressive disease pathways shows a number of new goals worth explored in NAFLD animal models and subsequently in pilot studies.